Core Insights - Booz Allen Hamilton is a significant player in the consulting services industry, specializing in management and technology consulting for government and commercial clients, with a strong presence in the U.S. and expertise in analytics, digital solutions, and cybersecurity [1] Financial Performance - On January 23, 2026, Truist Financial set a price target of $98 for Booz Allen Hamilton, while the stock was trading at $102.23, indicating a price difference of approximately -4.14% from the target [2] - Booz Allen reported quarterly earnings of $1.77 per share, surpassing the Zacks Consensus Estimate of $1.26 per share, marking an earnings surprise of over 40% compared to $1.55 per share in the same quarter last year [3] - The company's revenues for the quarter ended December 2025 were $2.62 billion, falling short of the Zacks Consensus Estimate by nearly 4% and lower than the $2.92 billion reported in the previous year [4] - Over the past four quarters, Booz Allen has exceeded consensus EPS estimates three times but has consistently missed revenue estimates [4] Strategic Adjustments - Booz Allen Hamilton has increased its profit outlook for the fiscal year due to successful cost-saving measures implemented in response to reductions in government-contract funding for consultants by the Trump administration, leading to improved financial performance [5]

Core Insights - Thermo Fisher Scientific Inc. (TMO) is set to release its fourth-quarter 2025 results on January 29, with earnings per share (EPS) expected to be $6.44, reflecting a 5.6% growth year-over-year [1][2][9] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for TMO's revenues is $11.95 billion, indicating a 4.9% increase from the same quarter last year [2][9] - TMO's earnings have consistently beaten estimates in the past four quarters, with an average surprise of 2.95% [1] Group 2: Segment Performance - The Analytical Instruments segment is anticipated to generate strong sales, particularly from electron microscopy and chromatography and mass spectrometry businesses [4] - The Life-Science Solutions segment is expected to report $2.89 billion in revenues, representing an 11.1% year-over-year improvement, driven by growth in the bioproduction business [10] - Specialty Diagnostics sales are projected to rise by 4.8% year-over-year, supported by new FDA approvals and product launches [9][13] Group 3: Recent Developments - TMO launched several new products, including the Orbitrap Exploris EFOX Mass Detector and new formulations for plasmid DNA production, which are expected to positively impact quarterly revenues [5][7] - The acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion is also anticipated to contribute favorably to TMO's performance [8] - TMO received FDA approvals for multiple diagnostic tests and launched new automated platforms, which are expected to enhance its top-line performance [11][12]

Core Insights - ACNB reported quarterly earnings of $1.35 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and showing a significant increase from $0.77 per share a year ago, resulting in an earnings surprise of +6.86% [1] - The company posted revenues of $37.18 million for the quarter ended December 2025, which fell short of the Zacks Consensus Estimate by 7.24%, compared to $26.92 million in the same quarter last year [2] - ACNB has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.23 on revenues of $40.19 million, while for the current fiscal year, the estimate is $5.20 on revenues of $164.53 million [7] - The estimate revisions trend for ACNB was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Banks - Southwest industry, to which ACNB belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ACNB's stock performance [5]

Core Viewpoint - Lazard (LAZ) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ending December 2025, with the consensus outlook indicating potential impacts on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for January 29, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The Zacks Consensus Estimate predicts quarterly earnings of $0.64 per share, reflecting an 18% decrease year-over-year, with revenues expected at $810.16 million, down 0.3% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 15%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Lazard aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is stronger for positive readings [9][10]. - Lazard currently holds a Zacks Rank of 5, which complicates predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Lazard exceeded the expected earnings of $0.41 per share by delivering $0.56, resulting in a surprise of +36.59% [13]. - Over the past four quarters, Lazard has consistently beaten consensus EPS estimates [14]. Conclusion - While Lazard does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for PulteGroup due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - PulteGroup is expected to report quarterly earnings of $2.78 per share, reflecting a year-over-year decrease of 20.6% [3]. - Revenues are projected to be $4.31 billion, down 12.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - A positive Earnings ESP of +2.10% suggests recent bullish sentiment among analysts, although the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [12]. Earnings Surprise History - PulteGroup has beaten consensus EPS estimates in the last four quarters, with a notable surprise of +3.50% in the most recent quarter [13][14]. Industry Context - M/I Homes, a competitor in the homebuilding sector, is expected to report earnings of $3.88 per share, down 17.6% year-over-year, with revenues of $1.16 billion, a decrease of 3.4% [18][19]. - M/I Homes has an Earnings ESP of -11.42% and has not beaten consensus EPS estimates in the last four quarters, indicating challenges in the industry [20].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Thermo Fisher Scientific, with a focus on how actual results will compare to estimates, which could significantly impact stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $6.44 per share, reflecting a +5.6% year-over-year change, and revenues of $11.95 billion, up 4.9% from the previous year [3]. - The consensus EPS estimate has been revised down by 0.09% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Thermo Fisher is lower than the consensus estimate, resulting in an Earnings ESP of -0.63%, indicating a bearish outlook from analysts [12]. - The stock currently holds a Zacks Rank of 3, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Thermo Fisher exceeded the expected earnings of $5.5 per share, achieving $5.79, which was a +5.27% surprise [13]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14]. Conclusion - While the company may not be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Core Viewpoint - Visa is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on January 29, with a consensus estimate of $3.14 per share, reflecting a +14.2% change year-over-year. Revenues are projected to be $10.68 billion, up 12.3% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised 0.01% higher in the last 30 days, indicating a slight positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Visa is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.23%. This suggests a bearish outlook from analysts regarding Visa's earnings prospects [12]. Historical Performance - In the last reported quarter, Visa had an earnings surprise of +0.34%, with actual earnings of $2.98 per share compared to the expected $2.97. Over the last four quarters, Visa has consistently beaten consensus EPS estimates [13][14]. Investment Considerations - Despite the potential for an earnings beat, other factors may influence stock movement, and the current combination of a negative Earnings ESP and a Zacks Rank of 3 complicates predictions for Visa's performance [15][17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in Blackstone Inc.'s earnings due to lower revenues, with a focus on how actual results will compare to estimates to influence stock price movements [1][2]. Earnings Expectations - Blackstone Inc. is expected to report quarterly earnings of $1.51 per share, reflecting a year-over-year decrease of 10.7% [3]. - Revenues are projected to be $3.61 billion, down 13.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.16% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Blackstone is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.44%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is significant mainly for positive readings [9][10]. - Blackstone's current Zacks Rank is 3, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Blackstone exceeded earnings expectations by delivering $1.52 per share against an expected $1.21, resulting in a surprise of +25.62% [13]. - The company has beaten consensus EPS estimates in each of the last four quarters [14]. Industry Comparison - Another player in the financial services sector, Houlihan Lokey, is expected to post earnings of $1.83 per share, indicating a year-over-year increase of 11.6% [18]. - Houlihan Lokey's revenues are projected to be $701.3 million, up 10.5% from the previous year, with a positive Earnings ESP of +2.19% [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Weyerhaeuser due to lower revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - Weyerhaeuser is expected to report a quarterly loss of $0.13 per share, reflecting a year-over-year change of -218.2% [3]. - Revenues are projected to be $1.58 billion, down 7.5% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 33.33% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Weyerhaeuser is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -21.52% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with significant predictive power for positive readings [9][10]. - Weyerhaeuser's current Zacks Rank is 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Weyerhaeuser was expected to post a loss of $0.07 per share but actually reported earnings of $0.06, resulting in a surprise of +185.71% [13]. - Over the past four quarters, Weyerhaeuser has beaten consensus EPS estimates three times [14]. Industry Comparison - Another company in the same industry, Potlatch, is expected to report a loss of $0.12 per share, indicating a year-over-year change of -271.4% [18]. - Potlatch's revenues are expected to be $226.7 million, down 12.2% from the previous year, with an Earnings ESP of +16.67% despite a Zacks Rank of 4 [19][20].

Core Viewpoint - Equity Bancshares (EQBK) reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.22 per share, and showing an increase from $1.1 per share a year ago, representing an earnings surprise of +3.56% [1] Financial Performance - The company posted revenues of $73.03 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.79%, compared to $58.29 million in the same quarter last year [2] - Over the last four quarters, Equity Bancshares has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Equity Bancshares shares have increased approximately 4.1% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] Future Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.19 on revenues of $81.7 million, and for the current fiscal year, it is $5.06 on revenues of $337.85 million [7] Industry Context - The Zacks Industry Rank for Banks - Northeast is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]